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Abstract
Drotecogin alfa (activated; DrotAA) was approved in 2001 by the
US Food and Drug Administration for the treatment of patients with
severe sepsis who are at high risk for death. The European Agency
for the Evaluation of Medical Products also recommended that
DrotAA could be administered to patients with severe sepsis and
multiple organ dysfunction when added to the best standard care.
Following the initial publication of the PROWESS (Protein C
Worldwide Evaluation in Severe Sepsis) findings, multiple
subgroup analyses supported the need for additional studies to
explore the various hypotheses raised by this study. This review
discusses all large clinical trials exploring the efficacy and safety of
DrotAA and proposes recommendations for the use of DrotAA in
severe sepsis.
Introduction
Drotecogin alfa (activated [DrotAA]; Xigris®; Eli Lilly and
Company, Indianapolis, IN, USA) is a recombinant form of the
natural anticoagulant activated protein C, and it was
approved by the US Food and Drug Administration (FDA) in
November 2001 for the treatment of adult patients with severe
sepsis at high risk of death (for instance, as indicated by
Acute Physiology and Chronic Health Evaluation [APACHE] II
score). In 2002 the European Agency for the Evaluation of
Medical Products recommended that its use be restricted to
patients with two or more sepsis-induced organ dysfunctions.
Together with these recommendations, other studies were
mandated by the FDA to explore the hypotheses generated
by subgroup analyses from PROWESS (Recombinant
Human Activated Protein C Worldwide Evaluation in Severe
Sepsis), which suggested that patients at low risk for death
might be harmed by DrotAA and that heparin prophylaxis
could reduce the survival benefit conferred by DrotAA. Finally,
at the time of FDA approval, no randomized controlled trial
had been conducted in children with severe sepsis. An FDA-
mandated paediatric trial, RESOLVE (REsearching severe
Sepsis and Organ dysfunction in children: a gLobal
perspective), was therefore conducted. This review
discusses the potential indications for DrotAA based on data
from all large clinical trials reported to date and provides
recommendations for its use.
Clinical trials
Table 1 provides a summary of the clinical trials in severe
sepsis evaluating DrotAA in adults and children. In the follow-
ing sections the individual trials are discussed in greater
detail. As in Table 1, the adult trials are discussed first
followed by the paediatric trials.
Adults
Phase II trial
In a phase II, placebo-controlled, dose-finding study [1], 131
patients with severe sepsis were analyzed. This study
demonstrated that an infusion of 24 μg/kg per hour for 96
continuous hours was associated with the greatest decrease
in D-dimer and interleukin-6 plasma levels, without significant
increase in bleeding risk compared with placebo. Also,
although not powered to evaluate this end-point, the 28-day,
all-cause mortality in the 24 to 32 μg/kg per hour arm was
reduced compared with placebo (34.1% versus 28.9%).
Based on these promising results, the 24 μg/kg per hour
dose was selected for use in the subsequent phase III
PROWESS study [2].
Phase III trial: PROWESS
This large, multicentre, randomized, double-blind, placebo-
controlled trial included 1,690 patients with sepsis and one
or more organ dysfunction that had been present for no
longer than 24 hours [2]. Patients were randomly assigned to
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receive either a continuous infusion of DrotAA at a dose of
24 μg/kg per hour or placebo for 96 hours. The primary end-
point was 28-day, all-cause mortality.
The study was stopped early after the second interim analysis
by an independent scientific board, because it met the stop-
ping rule for efficacy, established a priori. More than 70% of
the patients had shock, defined as cardiovascular dys-
function, and required mechanical ventilation.
On the basis of the prospectively defined primary analysis,
treatment with DrotAA was associated with absolute and
relative reductions in the risk for death of 6.1% and 19.4%,
respectively (P = 0.005). The mortality rate was 30.8% in the
placebo group and only 24.7% in the DrotAA group
(P = 0.005). Also, further analysis showed that patients
treated with DrotAA exhibited a faster resolution in cardio-
vascular and respiratory dysfunction [3]. However, the
incidence of serious bleeding was higher in the DrotAA group
than in the placebo group (3.5% versus 2.0%; P = 0.06).
Two patients treated with the drug developed intracerebral
haemorrhage (ICH) during the infusion period (0.2%).
After the initial report of the overall results, multiple subgroup
analyses were performed to explore whether the observed
efficacy of DrotAA could be attributed to one particular sub-
group of patients [4], and it confirmed that no specific
subpopulations were more likely to be harmed by the drug.
These subgroup analyses have important limitations, includ-
ing decreased statistical power and increased variance; they
should therefore be interpreted with caution. In PROWESS
more than 70 subgroup analyses have demonstrated a
consistent reduction in 28-day mortality when treated with
DrotAA. A survival benefit was observed independent of sex,
age, type of infection, type of pathogen, surgical status and
biochemical measures of disease severity, including baseline
Table 1
Summary of clinical trials with drotrecogin alfa (activated) in severe sepsis
Study Patients (n) Study type Main findings Comments
Adults
Phase II [1] 131 RCT Reduction in D-dimer and interleukin-6  Dose-finding study; optimal dose defined as 
plasma levels with DrotAA; reduction in  24 μg/kg per hour; benefit more pronounced 
28-day all-cause mortality (not significant);  in high-risk patients
no difference in bleeding events
PROWESS [2] 1,690 RCT Significant reduction in 28-day, all-cause  Increased survival benefit in patients at high 
mortality; faster resolution of organ  risk for death; no benefit in single organ 
dysfunction; consistent survival benefit in  dysfunction and low APACHE II score; 
more than 70 subgroups; reduced hospital  increased incidence of serious bleeding 
and 3 month mortality events
ENHANCE [11] 2,378 Open label Similar 28-day, all-cause mortality  Increased incidence of bleeding events 
compared with PROWESS; earlier  compared with PROWESS
intervention associated with improved 
outcome (<24 hours)
ADDRESS [12] 2,640 RCT No difference in 28-day and hospital  Increased incidence of bleeding events; 
all-cause mortality in patients at low risk  no increased incidence in ICH
for death
XPRESS [13] 1,994 RCT Concomitant heparin does not increase  Small increase in nonserious bleeding; 
28-day mortality; heparin prophylaxis  prophylactic heparin reduces incidence of 
should not be discontinued before DrotAA ischaemic stroke
Children
Phase Ib [14] 83 Open label Safety and pharmacokinetic/pharmaco- Safety similar to adults
dynamic study; pharmacokinetics/
pharmacodynamics similar to adults
RESOLVE [15] 477 RCT No difference in time to organ failure  More ICH in children younger than 60 days in 
resolution; no difference in 28-day  DrotAA arm
mortality; no difference in the incidence 
of serious bleeding events
ADDRESS, Administration of Drotrecogin alfa (activated) in early stage Severe Sepsis; APACHE, Acute Physiology and Chronic Health Evaluation;
DrotAA, drotecogin alfa (activated); ENHANCE, Extended Evaluation of Recombinant Human Activated Protein C; ICH, intracerebral haemorrhage;
PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; RCT, randomized controlled trial; RESOLVE,
REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective; XPRESS, Xigris and Prophylactic hepaRin Evaluation in
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protein C levels [5-7]. However, in patients with a single
organ dysfunction or APACHE II score of less than 20, no
apparent survival benefit was found.
This observation supported the decision of the FDA to
indicate the use of DrotAA for the treatment of patients with
severe sepsis at high risk for death. Also, based on the fact
that patients receiving concomitant heparin prophylaxis with
DrotAA had a lower survival benefit than did patients without
heparin prophylaxis, it was suggested that heparin may
interact with DrotAA. This finding prompted the FDA to
mandate a subsequent study to explore this hypothesis (see
XPRESS, below).
In a subsequent morbidity analysis, Angus and coworkers [8]
demonstrated there was no increase in resource use in
patients treated with DrotAA. Apart from the drug acquisition
cost, both placebo and DrotAA-treated patients had similar
intensive care unit and hospital lengths of stay [8]. In a long-
term follow-up study of the initially enrolled population, Laterre
and colleagues [9] showed that the hospital and 3-month
survival benefit from DrotAA was maintained. The 1-year and
2.5-year follow up by Angus and coworkers [10], which was
not adequately powered to evaluate a survival endpoint,
identified a nonsignificant benefit in patients treated with
DrotAA in the overall population but a highly significant benefit
in patients with baseline APACHE II score greater than 24.
Phase IIIB trial: ENHANCE
After PROWESS had been prematurely interrupted because
of efficacy and before FDA approval of DrotAA for the treat-
ment of severe sepsis, an open-label, single-arm trial
(ENHANCE [Extended Evaluation of Recombinant Human
Activated Protein C]) [11] was begun in March 2001. The
main objectives of ENHANCE were to provide more safety
and efficacy data on the use of DrotAA in patients with severe
sepsis. Despite the limitations of an unblinded study without a
placebo arm, selecting a population with similar inclusion and
exclusion criteria could allow some comparisons with
PROWESS with respect to the efficacy and safety of DrotAA.
The only major difference with PROWESS regarding the
inclusion criteria was the time window for intervention. In
ENHANCE, DrotAA infusion could be initiated up to 48 hours
after the first sepsis-induced organ dysfunction. A total of
2,378 patients received DrotAA in this study. Baseline
characteristics revealed that the enrolled population was
more severely ill than in the PROWESS population. More
patients required vasopressors and mechanical ventilation,
they had a higher mean Sequential Organ Failure Assess-
ment score, and they had undergone surgery before
enrolment. Therefore, the observed 28-day, all-cause mortality
of 25.3%, similar to that in PROWESS, was the main
reassuring result in terms of efficacy. The Kaplan-Meier
survival curve of ENHANCE was almost superimposable on
that of the DrotAA-treated arm of PROWESS (Figure 1).
In terms of safety, however, the incidence of serious bleeding
events was 3.6% in ENHANCE as compared with 2.4% in
PROWESS during the infusion period. Also, 15 patients
(0.6%) experienced one ICH event during the same period,
as opposed to two (0.2%) in PROWESS. This greater
proportion of bleeding complications might reflect the higher
proportion of surgical patients and the higher hepatic and
haematological Sequential Organ Failure Assessment scores
than in PROWESS.
The second important finding of this study was the potential
time dependency of the intervention’s effect. Patients treated
within the first 24 hours of organ dysfunction had a higher
survival rate than did patients treated later (22.9% versus
27.4%). Moreover, earlier treatment (within 24 hours) was
associated with improved survival, particularly in patients at
high risk for death.This difference persisted even after adjusting
for baseline differences in severity.
Phase IIIB trial: ADDRESS
After reviewing the subgroups analyses from PROWESS, the
FDA mandated that a study be conducted to evaluate the
efficacy and safety of DrotAA in adults with severe sepsis and
at low risk of death: ADDRESS (Administration of Drotre-
cogin alfa [activated] in early stage Severe Sepsis). Patients
eligible for this double-blind, placebo-controlled, randomized
trial were required to have been diagnosed with severe
sepsis, as defined by the presence of a suspected or known
infection but (in accordance with the country label for
Available online http://ccforum.com/content/11/S5/S5
Figure 1
Kaplan-Meier survival curves. Comparison of ENHANCE (Extended
Evaluation of Recombinant Human Activated Protein C) 28-day survival
with that of PROWESS (Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis). DrotAA, drotecogin alfa
(activated). Reproduced with permission from Vincent JL, Bernard GR,
Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R,
Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J:
Drotrecogin alfa (activated) treatment in severe sepsis from the global
open-label trial ENHANCE: further evidence for survival and safety and
implications for early treatment. Crit Care Med 2005, 33:2266-2277.
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nDrotAA) associated with a single sepsis-induced organ
failure, or if they had an APACHE II score below 25 [12].
Therefore, patients with two sepsis-related organ dys-
functions (ODs) but an APACHE II score below 25, and
patients with a single OD and an APACHE II score above 25
could be enrolled in the trial in the US and Europe,
respectively. The primary end-point was death from any cause
assessed 28 days after the start of the study drug infusion.
The study sample was initially calculated to detect a
statistically significant difference between placebo and
DrotAA at a two-sided P-value of 0.05.
The number of patients to be enrolled would have been
11,444. However, after a second interim analysis, the data
monitoring committee recommended early termination of
enrolment in accordance with the futility guidelines. The
chances of successfully meeting the defined objective was
less than 5% for a significant reduction in risk for death from
any cause at 28 days after starting the infusion. A total of
2,640 patients were finally enrolled and evaluated.
The 28-day, all-cause mortality was 17% in the placebo
versus 18.5% in the DrotAA arm (P = 0.34). Hospital mortality
rates were 20.5% and 20.6% in placebo and DrotAA groups,
respectively (P = 0.98). The expected increase in the risk for
bleeding associated with the use of DrotAA was confirmed.
Serious bleeding events occurred in 2.4% of DrotAA-treated
patients versus 1.2% in the placebo group (P = 0.02) during
the drug-infusion period. However, no difference was obser-
ved in the number of bleeding events involving the central
nervous system (CNS) with the use of DrotAA compared with
placebo (0.3% versus 0.2%).
Pre-specifed subgroup analyses were performed. Patients
with an APACHE II score of below 25 represented 87.7% of
the evaluated population. The 28-day and hospital mortality
rates were 16% and 18.8% in the placebo group, respec-
tively; the corresponding figures in DrotAA-treated patients
were 16.9% and 18.9% (not significant). In patients with an
APACHE II score above 24 and those who had two or more
sepsis-induced organ failures, the use of DrotAA was not
associated with a reduction in mortality, and the observed
results were not consistent. Indeed, although the 28-day
mortality rate was 24.7% in the placebo group as compared
with 29.5% in the DrotAA group for patients with an
APACHE II score above 25, in patients with multiple ODs the
placebo mortality was 21.9% as compared with 20.7% in
DrotAA-treated patients (not significant). Not only was the
sample size too small to detect a statistical difference, but
these data are difficult to compare with those from
PROWESS. Indeed, the mean APACHE II score in this
subgroup was lower in ADDRESS than in PROWESS. More
importantly, the 28-day mortality in placebo patients with an
APACHE II score above 24 in this study was 24.7% as
opposed to 43.7% in PROWESS. Similar observations were
made for patients with two or more organ failures, who had a
28-day mortality of 21.9% as compared with 33.9% in
PROWESS, which confirms that the enrolled patients in
ADDRESS were at lower risk for death.
Interestingly, heparin use at baseline apparently had no
influence on outcome in the two groups and in particular
within the placebo group. Finally, in a post hoc exploratory
analysis, the subgroup of patients who had undergone recent
surgery, had a single organ failure, and were receiving
DrotAA had a higher 28-day and hospital mortality compared
with the placebo group (20.7% versus 14.1% [P= 0.03] and
23.4% versus 19.8% [P = 0.26], respectively). In a small
subgroup of 98 patients in PROWESS with a single organ
failure and recent surgery, a similar effect was detected.
Increased postoperative bleeding and delayed drug adminis-
tration might have contributed to worsening organ failure and
higher mortality. Unfortunately, the limited data on surgery
and the absence of a statistically significant increase in the
bleeding event rate in the surgical population with one organ
failure did not allow confirmation of these hypotheses, but
they have led to the recommendation that DrotAA is not used
in this setting.
Phase IV trial: XPRESS
Subgroup analyses from PROWESS suggested that co-
administration of prophylactic heparin with DrotAA was
associated with a higher 28-day mortality, prompting the FDA
to request that the sponsor design a subsequent trial to
explore this hypothesis. XPRESS (Xigris and Prophylactic
hepaRin Evaluation in Severe Sepsis) was a randomized,
double-blind, phase IV, equivalence-design trial comparing
DrotAA plus heparin versus DrotAA plus placebo, which
enrolled 1,994 patients [13]. Unfractionated/low-molecular-
weight heparin or placebo were administered every 12 hours
during DrotAA infusion. If commercial heparin was being
administered at baseline, then it was a protocol requirement
to stop the heparin because patients were being randomly
assigned to heparin or placebo.
The 28-day mortality was 28.3% in the heparin arm as
compared with 31.9% in the placebo group (P = 0.08). The
incidence of all thrombotic events, including deep venous
thrombosis and pulmonary embolism, was low and no different
between the two groups (5.7% for heparin versus 7% for
placebo; not significant). However, ischaemic stroke incidence
was greater in the placebo group for the entire study period
(0.5% in heparin versus 1.8% in placebo; P = 0.01).
In subgroup analyses, heparin and placebo patients not
exposed to heparin at baseline had similar mortality rates.
Patients randomly assigned to placebo after heparin
exposure at baseline had a higher mortality than did patients
remaining on heparin. The difference in mortality was mostly
driven by non-sepsis-related deaths in the placebo group. A
greater number of these patients died from cardiac, cerebral,
bleeding and respiratory events as compared with the
Critical Care    Vol 11 Suppl 5 Laterre
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was 1.8% for placebo and 0.5% in the heparin group
(P = 0.01) for the 28-day follow up. Finally, the incidence of
‘any bleeding event’ was greater in the heparin group;
however, for serious bleeding events or ICH, no difference
was observed between the two groups. Results of the
XPRESS study indicate that prophylactic heparin adminis-
tration with DrotAA appears to be safe and that prophylactic
heparin should not be abruptly discontinued in patients with
severe sepsis or septic shock.
Children
Phase Ib trial
An open-label, nonrandomized, sequential study in children
was initiated in March 2000 [14]. A total of 83 paediatric
patients with severe sepsis (age range: ≥38 weeks of gesta-
tion to <18 years) were enrolled. The primary objectives were
to evaluate the safety and pharmacokinetic properties of
DrotAA in children, as well as the pharmacodynamic res-
ponses in adults with severe sepsis. One-third of the patients
had positive blood cultures, and in approximately 20% of
these the CNS was the site of infection.
The pharmacokinetic and pharmacodynamic effects of
DrotAA in children were similar to those observed in adults.
Two children (2.4%) had a serious bleeding event during the
infusion period, and in a third child with meningitis an ICH
occurred during the study period. Overall, the safety profile in
this paediatric population was comparable to that in adults
and supported a large phase III trial in children.
Phase III trial: RESOLVE
A phase III, randomized, double-blind, placebo-controlled trial
evaluated the efficacy and safety of DrotAA (24 μg/kg per
hour for 96 hours) in severe sepsis and included 477
paediatric patients (age range: ≥38 weeks of gestation to
<18 years) [15]. The primary end-point of RESOLVE was a
prospectively defined Composite Time to Complete Organ
Failure Resolution score. Mortality at 28-days, major
amputations and safety were secondary end-points. The
median age was close to 2.5 years, with more than 6% of
children being younger than 12 months. At baseline, one-third
of the population had purpura and more than 50% were
diagnosed with disseminated intravascular coagulation.
At the end of the defined follow-up period, there was no
significant difference between the two groups in Composite
Time to Complete Organ Failure Resolution score. Mortality
at 28 days was 17.5% in the placebo group and 17.2% in
the DrotAA group (P = 0.93). Hospital mortality also exhibited
no significant differences between treatment arms. Although
the bleeding event rates were similar in the two groups, there
were numerically more episodes of ICH in the DrotAA group
(11 [4.6%]) than in the placebo group (5 [2.1%]; P = 0.13).
This difference was predominantly observed in children
younger than 60 days at the time of enrolment.
Despite the limitations of this study (for example, small
population size with imbalances in baseline characteristics,
lower protein C levels than in PROWESS and potentially
insufficient dosing), DrotAA cannot be recommended for use
in children with severe sepsis.
Safety
The main expected adverse event in patients treated with
DrotAA is bleeding. A serious bleeding event was prospec-
tively defined in the PROWESS trial as a life-threatening
bleed, CNS haemorrhage, any bleeding event considered
serious by the investigator, or a requirement of three or more
red blood cell units for more than 2 consecutive days. The
same definition was used for all subsequent trials after
PROWESS. Table 2 summarizes bleeding events observed
in clinical trials, including all bleeding events, serious bleeding
events and CNS haemorrhage, when described. In all
randomized controlled trials, the incidence of bleeding was
increased in DrotAA-treated patients as compared with
placebo. Most bleeding occurred during the infusion period,
and more than half were procedure-related events. For the
28-day study period, serious bleeding events were observed
in 3.5% to 6.5% in DrotAA-treated patients as compared with
2.0% to 5.0% in the placebo group. These serious bleeding
events were often correlated with more pronounced baseline
severity, coagulopathy and platelet count below 30,000/mm3
during the infusion period. With the exception of ENHANCE,
the incidence of CNS bleeding during DrotAA infusion was
lower than 0.5% in all other trials.
In children included in randomized controlled trials, the overall
incidence of serious bleeding was no different in DrotAA-
treated than in placebo patients [15]. However, there were
numerically more CNS bleeding episodes in DrotAA-treated
children, and these occurred mainly in children younger than
2 months.
Post-marketing surveys
After DrotAA was launched, post-marketing surveys were
conducted in numerous countries throughout the world. The
main common findings of these surveys were a higher overall
mortality and incidence of serious bleeding events compared
with PROWESS [16,17]. However, the incidence of CNS
haemorrhage was found to be lower than 1% and similar to
incidence reported in randomized controlled trials. A survival
benefit for patients treated with DrotAA was suggested, but
this was assessed by using the expected mortality based on
severity scores or using the untreated population as
controls.
These findings indicate that, in everyday clinical practice, the
indications and use of the drug may largely differ from the
population initially enrolled in controlled studies. Indeed,
elevated severity scores and presence of relative or absolute
contraindications at baseline were much more common
based on post-marketing analyses than in PROWESS. Also,
Available online http://ccforum.com/content/11/S5/S5
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initiated well after 48 hours of organ dysfunction suggesting
that DrotAA was sometimes used as a rescue therapy. This
suggests that a better earlier severity assessment and
defined guidelines for use of DrotAA in patients with severe
sepsis who are at high risk for death should be established.
Clinical trial concerns
The initial publication of the PROWESS study report,
secondary subgroups analyses and additional clinical trials
were followed by multiple comments and criticisms [18-20].
Indeed, it was suggested that the positive results of
PROWESS had to be questioned for the following reasons:
an amendment took place during the study; recombinant
activated protein C was produced by a new cell lot midway
during the trial; blinding could ultimately not be assured
because there was a change in the placebo; some subgroup
analyses exhibited inconsistencies; and some sites had been
closed during the study and others opened. Additional
criticism was made after ADDRESS was stopped because of
futility and subgroups analyses compared with PROWESS.
Also, the bleeding risks of DrotAA were considered to be a
limitation.
These criticisms need to be addressed. First, the second
batch of recombinant activated protein C was demonstrated
to have the same in vitro activity as the first lot and appears
not to have played a role in the overall results. Unblinding
(because of the placebo change to saline in a single country
because human albumin was not allowed) is rather unlikely to
account for the difference in mortality.
The amendment that took place during PROWESS consisted
mainly of clarification on the definitions of inclusion and
exclusion criteria, and reminding investigators that patients
with advanced cancer or severe liver failure were not the
optimal population, especially because of the bleeding risks.
A small reduction in the number of patients with cancer was
observed after the amendment, but this occurred in both
treated and placebo arms. Interestingly, patients with
significant underlying conditions at baseline had an apparent
large benefit with DrotAA and therefore are not expected to
have positively influenced the second part of the trial. Also,
many investigators enrolled patients under both versions of
the protocol, and at these sites the survival benefit was
constant over the course of the study [21].
When the ADDRESS data were reviewed it was noted that,
because of the study design and different DrotAA labels in
the USA and Europe, a proportion of patients had multiple
organ dysfunction (MOD) or a baseline APACHE II score
above 25. For these two subgroups, the mortality results
were not consistent and differed from those in PROWESS.
Survival at day 28 was superior in placebo compared with
DrotAA for patients with an APACHE II score above 25, but it
was inferior in the presence of MOD. Not only are these
subgroups not adequately powered to allow conclusions to
be drawn, but also the placebo mortality in ADDRESS was
much lower than in the corresponding subgroups of
PROWESS (24.7% versus 43.7%), which supports the
evidence indicating that the two study populations should not
be compared.
Critical Care    Vol 11 Suppl 5 Laterre
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Table 2
Bleeding events for the 28-day study (period) in clinical trials evaluating DrotAA in severe sepsis
All bleeding events (%) Serious bleeding events (%) CNS bleeding (%)
Study DrotAA Placebo P DrotAA Placebo P DrotAA Placebo P
Adults
Phase II [1] ND ND 4.0 5.0 0.99 0 0 NS
PROWESS [2] ND ND 3.5 2.0 0.06 0.2 0 NS
ENHANCE [11] ND NA 6.5 NA 1.5 NA NA
ADDRESS [12] ND ND 3.9 2.2 0.01 0.5 0.4 NS
XPRESS [13]a 12.4 10.9 0.32 3.9 5.2 0.16 1.0 0.7 0.49
Children
Phase Ib [14] 20.5 NA 4.8 NA 2.4 NA NA
RESOLVE [15] ND ND 6.7 6.8 0.97 4.6 2.1 0.13
aFor the XPRESStrial all patients received drotecogin alfa (activated; DrotAA). Placebo refers to absence of concomitant heparin prophylaxis
during DrotAA infusion. ADDRESS, Administration of Drotrecogin alfa (activated) in early stage Severe Sepsis; ENHANCE, Extended Evaluation of
Recombinant Human Activated Protein C; NA, not applicable; ND, not described; PROWESS, Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis; RESOLVE, REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective;
XPRESS, Xigris and Prophylactic hepaRin Evaluation in Severe Sepsis.Conclusion
In light of the various clinical trials evaluating the efficacy and
safety of DrotAA in severe sepsis, we can conclude that
DrotAA can reduce mortality in patients with severe sepsis at
high risk for death. We can define this risk using severity
scores, such as high APACHE II score or multiple organ
failure, but probably also by sustained organ dysfunction that
is not improving or worsening despite optimal care and
adequate source control. However, this survival benefit is
achieved at the expense of a slight increase in the risk for
bleeding events, which can be minimized by adequate patient
selection. If indicated, the drug should be used within the first
24 hours of sepsis-induced organ dysfunction.
Heparin prophylaxis given before DrotAA administration
should not be interrupted because it is not associated with an
increased incidence of serious bleeding events and may
reduce the risk for ischaemic stroke in severe sepsis.
DrotAA is not indicated for use in patients at low risk for
mortality, as defined by a single organ failure or rapidly
improving MOD. Also, surgical patients at low risk for death
(single organ dysfunction) or with organ dysfunction not
induced by sepsis should not be considered appropriate
candidates for this therapy. Currently, DrotAA is not indicated
in children presenting with severe sepsis.
Future clinical trials should be designed to define better the
target population for DrotAA, based on clinical signs of
severity combined with a bedside biomarker. Also, the
optimal timing of intervention requires confirmation.
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